NASDAQ · Biotechnology

ERYTECH Pharma S.A. (ERYP) Stock

$0.78 +1.30% NASDAQ: ERYP Healthcare

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases.

Valuation

MetricValue
Price$0.78
Market Cap$47.38M
P/E Ratio-92.19
P/B Ratio0.90
P/S Ratio0.00
EPS (TTM)$-0.01
52-Week High$1.47
52-Week Low$0.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-0.98%
ROA-0.50%
ROCE-8.19%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.58
Current Ratio3.65

Annual Financials (USD)

Metric20182019202020212022
Revenue$4.0M$3.0M$0$0$0
Operating Profit$4.0M$5.0M$-69.0M$-57.0M$-3.0M
Net Profit$-38.0M$-63.0M$-73.0M$-54.0M$0
EPS$-2.13$-3.49$-3.99$-2.27$-0.01
Op Margin107.5%157.1%———

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$168.0M$119.0M$80.0M$67.0M$46.0M
Total Liabilities$22.0M$33.0M$54.0M$44.0M$22.0M
Cash$134.0M$73.0M$44.0M$34.0M$39.0M
Borrowings$2.0M$14.0M$27.0M$25.0M$14.0M

Latest News

Vallourec to supply pipes for Atapu 2 offshore project in Brazil Offshore Technology · Jul 23, 2026 Micron and Sandisk Are Surging: Can the Rally Last Through 2027? Motley Fool · Jul 23, 2026 1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds StockStory · Jul 23, 2026 CRIF India Launches Chennai Chapter of 'Credit Goes to HER' to Strengthen Women's Leadership in the Credit Ecosystem PR Newswire · Jul 23, 2026 Net Asset Value(s) Business Wire · Jul 23, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-39.0M$-43.0M$-52.0M$-57.0M$-32.0M
Investing Cash Flow$-29.0M$-40.0M$-3.0M$-1.0M$38.0M
Financing Cash Flow$-1.0M$0$25.0M$45.0M$-2.0M
Net Cash Flow$-51.0M$-61.0M$-29.0M$-11.0M$5.0M
Free Cash Flow$-53.0M$-63.0M$-53.0M$-57.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.27
EV / EBITDA3.55
FCF Yield-76.85%
Quick Ratio3.54
Interest Coverage-2.05
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALVRAlloVir, Inc. $9.81 +4.14% -1.89 $49.48M 0.00%
BLUEbluebird bio, Inc. $4.97 — -0.20 $48.67M 0.00%
CERCCerecor Inc. $2.93 -1.68% -0.53 $38.63M 0.00%
GRNAGreenLight Biosciences Holdings $0.30 -0.03% -0.24 $45.43M 0.00%
KRONKronos Bio, Inc. $0.88 +1.49% -0.62 $53.65M 0.00%

About ERYTECH Pharma S.A.

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.

ERYTECH Pharma S.A. is headquartered in FR.

ERYTECH Pharma S.A. (ERYP) stock trades at $0.78 with a market capitalization of $47.38M. The stock is valued at a price-to-earnings (P/E) ratio of -92.19, price-to-book of 0.90, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.30 and $1.47, and currently trades 46.9% below its 52-week high.

On profitability, ERYTECH Pharma S.A. generates a return on equity (ROE) of -0.98%, return on capital employed of -8.19%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.erytech.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1211.40 +3.85% JNJ Johnson & Johnson $253.91 +2.13% ABBV AbbVie Inc. $283.52 +3.34% MRK Merck & Company, Inc. Common Stock (new) $147.37 +3.79% UNH UnitedHealth Group Incorporated Common Stock (DE) $395.62 +4.73% NVS Novartis AG $146.88 +3.14% AZN AstraZeneca PLC $162.03 +3.99% TMO Thermo Fisher Scientific Inc $673.20 +1.53% AMGN Amgen Inc. $426.11 +3.21% GILD Gilead Sciences, Inc. $153.54 +3.80% ABT Abbott Laboratories $102.97 +0.35% NVO Novo Nordisk A/S $38.12 +0.16%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides